{"transactions":[{"id":857711,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":62492,"kind":"person","name":"Mitchell Shawnte","position":1,"cik":"0001749432","reported_name":"Mitchell Shawnte","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-05T20:00:07.000Z","date":"2026-03-04","kind":"exercise","planned":false,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the option vest on February 28, 2026 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":410000,"derivative":{"exercise_price":4.37,"expiration_date":"2035-02-27","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001749432-26-000004","document":"form4-03052026_080301.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1749432/000174943226000004/form4-03052026_080301.xml","form_type":"4"}},{"id":857710,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":62492,"kind":"person","name":"Mitchell Shawnte","position":1,"cik":"0001749432","reported_name":"Mitchell Shawnte","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-05T20:00:07.000Z","date":"2026-03-03","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the option vest on February 28, 2026 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":435000,"derivative":{"exercise_price":4.37,"expiration_date":"2035-02-27","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001749432-26-000004","document":"form4-03052026_080301.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1749432/000174943226000004/form4-03052026_080301.xml","form_type":"4"}},{"id":857709,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":62492,"kind":"person","name":"Mitchell Shawnte","position":1,"cik":"0001749432","reported_name":"Mitchell Shawnte","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Comon Stock","published_at":"2026-03-05T20:00:07.000Z","date":"2026-03-04","kind":"sale","planned":false,"acquired":false,"shares":233,"price":24.69,"value":5752.77,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $24.69, and the range of prices were between $24.68 and $24.70. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001749432-26-000004","document":"form4-03052026_080301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1749432/000174943226000004/form4-03052026_080301.xml","form_type":"4"}},{"id":857708,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":62492,"kind":"person","name":"Mitchell Shawnte","position":1,"cik":"0001749432","reported_name":"Mitchell Shawnte","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2026-03-05T20:00:07.000Z","date":"2026-03-04","kind":"sale","planned":false,"acquired":false,"shares":24767,"price":24.25,"value":600599.75,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $24.25, and the range of prices were between $23.68 and $24.64. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":233,"source":{"system":"sec-edgar","filing":"0001749432-26-000004","document":"form4-03052026_080301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1749432/000174943226000004/form4-03052026_080301.xml","form_type":"4"}},{"id":857707,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":62492,"kind":"person","name":"Mitchell Shawnte","position":1,"cik":"0001749432","reported_name":"Mitchell Shawnte","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2026-03-05T20:00:07.000Z","date":"2026-03-04","kind":"exercise","planned":false,"acquired":true,"shares":25000,"price":4.37,"value":109250.0,"ownership":{"direct":true},"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001749432-26-000004","document":"form4-03052026_080301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1749432/000174943226000004/form4-03052026_080301.xml","form_type":"4"}},{"id":857706,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":62492,"kind":"person","name":"Mitchell Shawnte","position":1,"cik":"0001749432","reported_name":"Mitchell Shawnte","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2026-03-05T20:00:07.000Z","date":"2026-03-03","kind":"sale","planned":false,"acquired":false,"shares":15000,"price":23.01,"value":345150.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average sale price for the transaction reported was $23.01, and the range of prices were between $22.89 and $23.19. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001749432-26-000004","document":"form4-03052026_080301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1749432/000174943226000004/form4-03052026_080301.xml","form_type":"4"}},{"id":857705,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":62492,"kind":"person","name":"Mitchell Shawnte","position":1,"cik":"0001749432","reported_name":"Mitchell Shawnte","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2026-03-05T20:00:07.000Z","date":"2026-03-03","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":4.37,"value":65550.0,"ownership":{"direct":true},"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001749432-26-000004","document":"form4-03052026_080301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1749432/000174943226000004/form4-03052026_080301.xml","form_type":"4"}},{"id":918939,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":62492,"kind":"person","name":"Mitchell Shawnte","position":1,"cik":"0001749432","reported_name":"Mitchell Shawnte","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Performance Stock Options (Right to Buy)","published_at":"2026-02-04T21:30:06.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":56250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The performance-based stock options will be eligible to vest during two distinct performance periods, each beginning on February 2, 2026 and ending on December 31, 2029 and December 31, 2030, respectively, based on the Issuer's stock price trading at certain pre-determined price thresholds as measured by the average closing price per share of the Issuer's stock over a consecutive thirty (30) day trading period during each such performance period. Once a price threshold is achieved, the portion of the award related to such threshold will vest upon the date set forth in the certification by the Compensation Committee certifying that such price threshold was achieved, subject to the Reporting Person's continuous service as of the applicable certification date."}],"balance_after":56250,"derivative":{"exercise_price":25.65,"expiration_date":"2036-02-01","underlying":"Common Stock","underlying_shares":56250},"source":{"system":"sec-edgar","filing":"0001749432-26-000002","document":"form4-02042026_090203.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1749432/000174943226000002/form4-02042026_090203.xml","form_type":"4"}},{"id":918938,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":62492,"kind":"person","name":"Mitchell Shawnte","position":1,"cik":"0001749432","reported_name":"Mitchell Shawnte","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-04T21:30:06.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":220000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on February 2, 2027, and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":220000,"derivative":{"exercise_price":25.65,"expiration_date":"2036-02-01","underlying":"Common Stock","underlying_shares":220000},"source":{"system":"sec-edgar","filing":"0001749432-26-000002","document":"form4-02042026_090203.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1749432/000174943226000002/form4-02042026_090203.xml","form_type":"4"}},{"id":1235078,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":62492,"kind":"person","name":"Mitchell Shawnte","position":1,"cik":"0001749432","reported_name":"Mitchell Shawnte","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-03T16:18:17.000Z","date":"2025-02-28","kind":"grant","planned":false,"acquired":true,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on February 28, 2026 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":450000,"derivative":{"exercise_price":4.37,"expiration_date":"2035-02-27","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0001415889-25-006154","document":"form4-03032025_090314.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1749432/000141588925006154/form4-03032025_090314.xml","form_type":"4"}},{"id":2341581,"issuer":{"id":129305,"kind":"organization","name":"ZOGENIX, INC.","symbol":"ZGNX"},"owners":[{"id":62492,"kind":"person","name":"Mitchell Shawnte","position":1,"cik":"0001749432","reported_name":"Mitchell Shawnte","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, GC & Secretary"}}],"security":"Restricted Stock Units","published_at":"2022-03-09T19:06:04.000Z","date":"2022-03-07","kind":"disposition_to_issuer","acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit represents a contingent right to receive one Share."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, each restricted stock unit (including performance stock units) was canceled and converted into the right to receive an amount in cash equal to (i) the product of (A) the total number of Shares subject to (or deliverable under) such restricted stock unit (with any performance conditions deemed achieved at maximum levels with respect to any performance stock unit) multiplied by (B) the Cash Amount, and (ii) one CVR with respect to each Share subject to such restricted stock unit."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a \"Company Option\") with an exercise price less than $26.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive an amount in cash equal to, subject to applicable tax withholding, the product of (i) the excess, if any of the Cash Amount over the exercise price per Share underlying such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Options and one CVR; (b) each Company Option with an exercise price equal to or greater than $26.00 but less than $28.00 (each, an \"Out of the Money Option\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from Footnote 3) was canceled and converted into the right to receive, subject to the terms of the Merger Agreement, if and when (and only if and when) payments in respect of CVRs are required to be made, $28.00 in cash (less the applicable exercise price per Share subject to such Out of the Money Option); (c) each Company Option with an exercise price equal to or greater than $28.00, was canceled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Not applicable."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-22-010293","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1375151/000089924322010293/doc4.xml","form_type":"4"}},{"id":2341580,"issuer":{"id":129305,"kind":"organization","name":"ZOGENIX, INC.","symbol":"ZGNX"},"owners":[{"id":62492,"kind":"person","name":"Mitchell Shawnte","position":1,"cik":"0001749432","reported_name":"Mitchell Shawnte","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, GC & Secretary"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-09T19:06:04.000Z","date":"2022-03-07","kind":"disposition_to_issuer","acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a \"Company Option\") with an exercise price less than $26.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive an amount in cash equal to, subject to applicable tax withholding, the product of (i) the excess, if any of the Cash Amount over the exercise price per Share underlying such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Options and one CVR; (b) each Company Option with an exercise price equal to or greater than $26.00 but less than $28.00 (each, an \"Out of the Money Option\"),"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) was canceled and converted into the right to receive, subject to the terms of the Merger Agreement, if and when (and only if and when) payments in respect of CVRs are required to be made, $28.00 in cash (less the applicable exercise price per Share subject to such Out of the Money Option); (c) each Company Option with an exercise price equal to or greater than $28.00, was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a \"Company Option\") with an exercise price less than $26.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive an amount in cash equal to, subject to applicable tax withholding, the product of (i) the excess, if any of the Cash Amount over the exercise price per Share underlying such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Options and one CVR; (b) each Company Option with an exercise price equal to or greater than $26.00 but less than $28.00 (each, an \"Out of the Money Option\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from Footnote 3) was canceled and converted into the right to receive, subject to the terms of the Merger Agreement, if and when (and only if and when) payments in respect of CVRs are required to be made, $28.00 in cash (less the applicable exercise price per Share subject to such Out of the Money Option); (c) each Company Option with an exercise price equal to or greater than $28.00, was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":18.76,"expiration_date":"2031-03-25","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-22-010293","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1375151/000089924322010293/doc4.xml","form_type":"4"}},{"id":2341579,"issuer":{"id":129305,"kind":"organization","name":"ZOGENIX, INC.","symbol":"ZGNX"},"owners":[{"id":62492,"kind":"person","name":"Mitchell Shawnte","position":1,"cik":"0001749432","reported_name":"Mitchell Shawnte","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, GC & Secretary"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-09T19:06:04.000Z","date":"2022-03-07","kind":"disposition_to_issuer","acquired":false,"shares":110000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a \"Company Option\") with an exercise price less than $26.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive an amount in cash equal to, subject to applicable tax withholding, the product of (i) the excess, if any of the Cash Amount over the exercise price per Share underlying such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Options and one CVR; (b) each Company Option with an exercise price equal to or greater than $26.00 but less than $28.00 (each, an \"Out of the Money Option\"),"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) was canceled and converted into the right to receive, subject to the terms of the Merger Agreement, if and when (and only if and when) payments in respect of CVRs are required to be made, $28.00 in cash (less the applicable exercise price per Share subject to such Out of the Money Option); (c) each Company Option with an exercise price equal to or greater than $28.00, was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a \"Company Option\") with an exercise price less than $26.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive an amount in cash equal to, subject to applicable tax withholding, the product of (i) the excess, if any of the Cash Amount over the exercise price per Share underlying such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Options and one CVR; (b) each Company Option with an exercise price equal to or greater than $26.00 but less than $28.00 (each, an \"Out of the Money Option\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from Footnote 3) was canceled and converted into the right to receive, subject to the terms of the Merger Agreement, if and when (and only if and when) payments in respect of CVRs are required to be made, $28.00 in cash (less the applicable exercise price per Share subject to such Out of the Money Option); (c) each Company Option with an exercise price equal to or greater than $28.00, was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":26.68,"expiration_date":"2030-04-19","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0000899243-22-010293","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1375151/000089924322010293/doc4.xml","form_type":"4"}},{"id":2341578,"issuer":{"id":129305,"kind":"organization","name":"ZOGENIX, INC.","symbol":"ZGNX"},"owners":[{"id":62492,"kind":"person","name":"Mitchell Shawnte","position":1,"cik":"0001749432","reported_name":"Mitchell Shawnte","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, GC & Secretary"}}],"security":"Common Stock","published_at":"2022-03-09T19:06:04.000Z","date":"2022-03-07","kind":"other","acquired":false,"shares":605,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 18, 2022, (the \"Merger Agreement\"), among UCB S.A., a societe anonyme formed under the laws of Belgium (\"Parent\"), Zinc Merger Sub, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent (\"Purchaser\") and the Issuer, pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of March 7, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was canceled and converted into the right to receive $26.00 in cash (the \"Cash Amount\") plus a contingent value right (\"CVR\"), which CVR represents the right to receive a contingent payment of $2.00 which amount will become payable, if at all, if a specified milestone is achieved on or prior to December 31, 2023."},{"field":"shares","element":"transactionShares","label":"F1","text":"Acquired under the Issuer's Employee Stock Purchase Plan since the last filing by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 18, 2022, (the \"Merger Agreement\"), among UCB S.A., a societe anonyme formed under the laws of Belgium (\"Parent\"), Zinc Merger Sub, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent (\"Purchaser\") and the Issuer, pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of March 7, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was canceled and converted into the right to receive $26.00 in cash (the \"Cash Amount\") plus a contingent value right (\"CVR\"), which CVR represents the right to receive a contingent payment of $2.00 which amount will become payable, if at all, if a specified milestone is achieved on or prior to December 31, 2023."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-010293","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1375151/000089924322010293/doc4.xml","form_type":"4"}},{"id":2767854,"issuer":{"id":129305,"kind":"organization","name":"ZOGENIX, INC.","symbol":"ZGNX"},"owners":[{"id":62492,"kind":"person","name":"Mitchell Shawnte","position":1,"cik":"0001749432","reported_name":"Mitchell Shawnte","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, GC and Secretary"}}],"security":"Restricted Stock Units","published_at":"2021-03-30T21:25:23.000Z","date":"2021-03-26","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Zogenix common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vests in four equal installments on each of March 15, 2022, 2023, 2024 and 2025, subject to the reporting person's continuous service to the Company on such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Not applicable."}],"balance_after":12500,"derivative":{"underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001375151-21-000037","document":"wf-form4_161715390667661.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1375151/000137515121000037/wf-form4_161715390667661.xml","form_type":"4"}},{"id":2767853,"issuer":{"id":129305,"kind":"organization","name":"ZOGENIX, INC.","symbol":"ZGNX"},"owners":[{"id":62492,"kind":"person","name":"Mitchell Shawnte","position":1,"cik":"0001749432","reported_name":"Mitchell Shawnte","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, GC and Secretary"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-30T21:25:23.000Z","date":"2021-03-26","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award shall vest in a series of forty-eight (48) successive, equal monthly installments, with the first vest date occurring on April 15, 2021, subject to the reporting person's continued service to the Company on the applicable vesting dates."}],"balance_after":25000,"derivative":{"exercise_price":18.76,"expiration_date":"2031-03-26","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001375151-21-000037","document":"wf-form4_161715390667661.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1375151/000137515121000037/wf-form4_161715390667661.xml","form_type":"4"}},{"id":3172327,"issuer":{"id":129305,"kind":"organization","name":"ZOGENIX, INC.","symbol":"ZGNX"},"owners":[{"id":62492,"kind":"person","name":"Mitchell Shawnte","position":1,"cik":"0001749432","reported_name":"Mitchell Shawnte","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, GC and Secretary"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-21T21:37:12.000Z","date":"2020-04-20","kind":"grant","acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the total number of shares subject to the option vests on the one-year anniversary of the date of grant and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the option on each month thereafter, subject to continued service to us through each vesting date."}],"balance_after":110000,"derivative":{"exercise_price":26.68,"expiration_date":"2030-04-19","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001375151-20-000063","document":"wf-form4_158751941465958.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1375151/000137515120000063/wf-form4_158751941465958.xml","form_type":"4"}},{"id":3200775,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":62492,"kind":"person","name":"Mitchell Shawnte","position":1,"cik":"0001749432","reported_name":"Mitchell Shawnte","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GC and Corporate Affairs"}}],"security":"Stock Option (right to buy)","published_at":"2020-03-19T22:34:50.000Z","date":"2020-02-18","kind":"grant","acquired":true,"shares":134800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in three approximately equal annual installments beginning on February 17, 2021."}],"balance_after":134800,"derivative":{"exercise_price":0.498,"expiration_date":"2030-02-17","underlying":"Common Stock","underlying_shares":134800},"source":{"system":"sec-edgar","filing":"0001019056-20-000243","document":"mitchell.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905620000243/mitchell.xml","form_type":"4"}},{"id":3380331,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":62492,"kind":"person","name":"Mitchell Shawnte","position":1,"cik":"0001749432","reported_name":"Mitchell Shawnte","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GC and Corporate Affairs"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-06T01:55:37.000Z","date":"2019-11-01","kind":"grant","acquired":true,"shares":120968,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest on November 1, 2020, the one-year anniversary of the grant date."}],"balance_after":120968,"derivative":{"exercise_price":0.576,"expiration_date":"2029-10-31","underlying":"Common Stock","underlying_shares":120968},"source":{"system":"sec-edgar","filing":"0001019056-19-000618","document":"mitchell.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905619000618/mitchell.xml","form_type":"4"}},{"id":3619214,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":62492,"kind":"person","name":"Mitchell Shawnte","position":1,"cik":"0001749432","reported_name":"Mitchell Shawnte","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GC and Corporate Affairs"}}],"security":"Restricted Stock Unit","published_at":"2019-03-05T02:08:10.000Z","date":"2019-03-01","kind":"exercise","acquired":false,"shares":6787,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into shares of the Issuer's common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 1, 2016 the reporting person was granted 20,365 restricted stock units. 6,789 shares of common stock underlying the restricted stock units vested on each of March 1, 2017 and March 1, 2018, and the remaining 6,787 shares vested on March 1, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 1, 2016 the reporting person was granted 20,365 restricted stock units. 6,789 shares of common stock underlying the restricted stock units vested on each of March 1, 2017 and March 1, 2018, and the remaining 6,787 shares vested on March 1, 2019."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6787},"source":{"system":"sec-edgar","filing":"0001019056-19-000182","document":"mitchell.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905619000182/mitchell.xml","form_type":"4"}},{"id":3619213,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":62492,"kind":"person","name":"Mitchell Shawnte","position":1,"cik":"0001749432","reported_name":"Mitchell Shawnte","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GC and Corporate Affairs"}}],"security":"Stock Option (right to buy)","published_at":"2019-03-05T02:08:10.000Z","date":"2019-02-28","kind":"grant","acquired":true,"shares":67400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in three approximately equal annual installments beginning on February 28, 2020."}],"balance_after":67400,"derivative":{"exercise_price":1.52,"expiration_date":"2029-02-28","underlying":"Common Stock","underlying_shares":67400},"source":{"system":"sec-edgar","filing":"0001019056-19-000182","document":"mitchell.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905619000182/mitchell.xml","form_type":"4"}},{"id":3619212,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":62492,"kind":"person","name":"Mitchell Shawnte","position":1,"cik":"0001749432","reported_name":"Mitchell Shawnte","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GC and Corporate Affairs"}}],"security":"Common Stock","published_at":"2019-03-05T02:08:10.000Z","date":"2019-03-01","kind":"tax_withholding","acquired":false,"shares":2012,"price":1.57,"value":3158.84,"ownership":{"direct":true},"balance_after":80527,"source":{"system":"sec-edgar","filing":"0001019056-19-000182","document":"mitchell.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905619000182/mitchell.xml","form_type":"4"}},{"id":3619211,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":62492,"kind":"person","name":"Mitchell Shawnte","position":1,"cik":"0001749432","reported_name":"Mitchell Shawnte","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GC and Corporate Affairs"}}],"security":"Common Stock","published_at":"2019-03-05T02:08:10.000Z","date":"2019-03-01","kind":"exercise","acquired":true,"shares":6787,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into shares of the Issuer's common stock on a one-for-one basis."}],"balance_after":82539,"source":{"system":"sec-edgar","filing":"0001019056-19-000182","document":"mitchell.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905619000182/mitchell.xml","form_type":"4"}},{"id":3846254,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":62492,"kind":"person","name":"Mitchell Shawnte","position":1,"cik":"0001749432","reported_name":"Mitchell Shawnte","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GC and Corporate Affairs"}}],"security":"Restricted Stock Units","published_at":"2018-08-13T20:45:48.000Z","date":"2018-08-09","kind":"exercise","acquired":false,"shares":1630,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into shares of the Issuer's common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On August 10, 2015, the reporting person was granted 4,892 restricted stock units. 1,631 shares of common stock underlying the restricted stock units vested on each of August 9, 2016 and August 9, 2017, and 1,630 vested on August 9, 2018."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On August 10, 2015, the reporting person was granted 4,892 restricted stock units. 1,631 shares of common stock underlying the restricted stock units vested on each of August 9, 2016 and August 9, 2017, and 1,630 vested on August 9, 2018."}],"balance_after":6787,"derivative":{"underlying":"Common Stock","underlying_shares":1630},"source":{"system":"sec-edgar","filing":"0001019056-18-000956","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905618000956/ownership.xml","form_type":"4"}},{"id":3846253,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":62492,"kind":"person","name":"Mitchell Shawnte","position":1,"cik":"0001749432","reported_name":"Mitchell Shawnte","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GC and Corporate Affairs"}}],"security":"Common Stock","published_at":"2018-08-13T20:45:48.000Z","date":"2018-08-09","kind":"tax_withholding","acquired":false,"shares":383,"price":4.5,"value":1723.5,"ownership":{"direct":true},"balance_after":75752,"source":{"system":"sec-edgar","filing":"0001019056-18-000956","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905618000956/ownership.xml","form_type":"4"}},{"id":3846252,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":62492,"kind":"person","name":"Mitchell Shawnte","position":1,"cik":"0001749432","reported_name":"Mitchell Shawnte","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GC and Corporate Affairs"}}],"security":"Common Stock","published_at":"2018-08-13T20:45:48.000Z","date":"2018-08-09","kind":"exercise","acquired":true,"shares":1630,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into shares of the Issuer's common stock on a one-for-one basis."}],"balance_after":76135,"source":{"system":"sec-edgar","filing":"0001019056-18-000956","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905618000956/ownership.xml","form_type":"4"}}]}